Zhang, X., Song, K., Tong, F., Fei, M., Guo, H., Lu, Z., ... & Zheng, C. (2020). First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood advances, 4(7), 1307.

doi: 10.1182/bloodadvances.2020001907

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160284/

Smith College

- First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
- A relation between blood type and COVID-19 was found

Blood Advances Papers Related COVID-19 Patient  Comorbidities 

First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab

- 187 patients were separated into 4 different groups based on blood types (A, B, AB, O)
- Type A and Type B blood were the most common in the patients
- Those with Type A blood were at greater risk of developing COVID-19
- Those with Type O blood were at lower risk of developing COVID-19
- The data for Type AB blood is not statistically significant, since the p-value is greater than 0.05

Epidemiological relation
- The OR for Type A blood compared to other blood types came out to be 1.544, indicating a 54% increased risk of getting COVID-19
- The OR for Type O blood came out to be 0.649, indicating a 35% decreased risk of developing COVID-19


Learn Before

Related